BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 35904529)

  • 1. The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature.
    Salas M; Petracek J; Yalamanchili P; Aimer O; Kasthuril D; Dhingra S; Junaid T; Bostic T
    Pharmaceut Med; 2022 Oct; 36(5):295-306. PubMed ID: 35904529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of Artificial Intelligence to Support the Automatic Coding of Patient Adverse Drug Reaction Reports, Using Nationwide Pharmacovigilance Data.
    Martin GL; Jouganous J; Savidan R; Bellec A; Goehrs C; Benkebil M; Miremont G; Micallef J; Salvo F; Pariente A; Létinier L;
    Drug Saf; 2022 May; 45(5):535-548. PubMed ID: 35579816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial intelligence-powered pharmacovigilance: A review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets.
    Li Y; Tao W; Li Z; Sun Z; Li F; Fenton S; Xu H; Tao C
    J Biomed Inform; 2024 Apr; 152():104621. PubMed ID: 38447600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Artificial Intelligence for Drug Toxicity and Safety.
    Basile AO; Yahi A; Tatonetti NP
    Trends Pharmacol Sci; 2019 Sep; 40(9):624-635. PubMed ID: 31383376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Artificial Intelligence Based on Machine Learning in Pharmacovigilance: A Scoping Review.
    Kompa B; Hakim JB; Palepu A; Kompa KG; Smith M; Bain PA; Woloszynek S; Painter JL; Bate A; Beam AL
    Drug Saf; 2022 May; 45(5):477-491. PubMed ID: 35579812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and Cats.
    Xu X; Mazloom R; Goligerdian A; Staley J; Amini M; Wyckoff GJ; Riviere J; Jaberi-Douraki M
    Top Companion Anim Med; 2019 Dec; 37():100366. PubMed ID: 31837760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial Intelligence for Unstructured Healthcare Data: Application to Coding of Patient Reporting of Adverse Drug Reactions.
    Létinier L; Jouganous J; Benkebil M; Bel-Létoile A; Goehrs C; Singier A; Rouby F; Lacroix C; Miremont G; Micallef J; Salvo F; Pariente A
    Clin Pharmacol Ther; 2021 Aug; 110(2):392-400. PubMed ID: 33866552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations?
    Pariente A; Micallef J; Lahouegue A; Molimard M; Auffret M; Chouchana L; Denis B; Faillie JL; Grandvuillemin A; Letinier L; Pierron E; Pons C; Pujade I; Rubino H; Salvo F
    Therapie; 2023; 78(1):131-143. PubMed ID: 36572627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intelligent Telehealth in Pharmacovigilance: A Future Perspective.
    Edrees H; Song W; Syrowatka A; Simona A; Amato MG; Bates DW
    Drug Saf; 2022 May; 45(5):449-458. PubMed ID: 35579810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artificial Intelligence Within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation.
    Mockute R; Desai S; Perera S; Assuncao B; Danysz K; Tetarenko N; Gaddam D; Abatemarco D; Widdowson M; Beauchamp S; Cicirello S; Mingle E
    Pharmaceut Med; 2019 Apr; 33(2):109-120. PubMed ID: 31933254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Machine learning models to detect and predict patient safety events using electronic health records: A systematic review.
    Deimazar G; Sheikhtaheri A
    Int J Med Inform; 2023 Dec; 180():105246. PubMed ID: 37837710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial Intelligence and the Future of the Drug Safety Professional.
    Danysz K; Cicirello S; Mingle E; Assuncao B; Tetarenko N; Mockute R; Abatemarco D; Widdowson M; Desai S
    Drug Saf; 2019 Apr; 42(4):491-497. PubMed ID: 30343417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis.
    Alroobaea R; Rubaiee S; Hanbazazah AS; Jahrami H; Garbarino S; Damiani G; Wu J; Bragazzi NL
    Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):4074-4081. PubMed ID: 35731078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial Intelligent Context-Aware Machine-Learning Tool to Detect Adverse Drug Events from Social Media Platforms.
    Roosan D; Law AV; Roosan MR; Li Y
    J Med Toxicol; 2022 Oct; 18(4):311-320. PubMed ID: 36097239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An artificial intelligence algorithm for co-clustering to help in pharmacovigilance before and during the COVID-19 pandemic.
    Destere A; Marchello G; Merino D; Othman NB; Gérard AO; Lavrut T; Viard D; Rocher F; Corneli M; Bouveyron C; Drici MD
    Br J Clin Pharmacol; 2024 May; 90(5):1258-1267. PubMed ID: 38332645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Pilot, Predictive Surveillance Model in Pharmacovigilance Using Machine Learning Approaches.
    De Abreu Ferreira R; Zhong S; Moureaud C; Le MT; Rothstein A; Li X; Wang L; Patwardhan M
    Adv Ther; 2024 Jun; 41(6):2435-2445. PubMed ID: 38704799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance.
    Kassekert R; Grabowski N; Lorenz D; Schaffer C; Kempf D; Roy P; Kjoersvik O; Saldana G; ElShal S
    Drug Saf; 2022 May; 45(5):439-448. PubMed ID: 35579809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Will the future of pharmacovigilance be more automated?
    Salvo F; Micallef J; Lahouegue A; Chouchana L; Létinier L; Faillie JL; Pariente A
    Expert Opin Drug Saf; 2023; 22(7):541-548. PubMed ID: 37435796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Biomarkers in Pharmacovigilance: A Systematic Review of the Literature.
    Salas M; Gossell-Williams M; Yalamanchili P; Dhingra S; Malikova MA; Aimer O; Junaid T
    Biomark Insights; 2023; 18():11772719231164528. PubMed ID: 37077840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.